Megadalton joins Waters' Immerse Cambridge labs Megadalton Solutions has expanded its collaboration with Waters to bring its charge detection mass spectrometry technology to a broader set of biopharma customers by joining Waters' Immerse Cambridge lab.
Obsidian, MD Anderson partner on solid tumor cell therapy Obsidian Therapeutics and the University of Texas MD Anderson Cancer Center have entered a multiyear strategic collaboration for the research and development of novel engineered tumor infiltrating lymphocytes for the treatment of solid tumors.
Vivet, Pfizer to begin Wilson's disease gene therapy trial The U.S. Food and Drug Administration (FDA) has cleared Vivet Therapeutics' investigational new drug application for the Gateway study, a phase I/II study evaluating Vivet's VTX-801, a proprietary, investigational gene therapy for the treatment of Wilson's disease.
Factor Bioscience defends gene editing patent The Russian Patent Office has denied a request by Advanced Gene and Cell Technologies to invalidate Factor Bioscience's patent (No. 2,691,027), which covers gene edited hematopoietic cells made using messenger RNA.